Alberta, Canada-based Willow Biosciences (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. A recent article discussing Willow Biosciences reads, “The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by chief scientific officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional nonpathway yet commercially essential accessory genes. . . . Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell ‘factory.’ This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days — far less time than traditional plant-based extraction methods.”
To view the full article, visit http://ibn.fm/8JliU
About Willow Biosciences Inc.
Headquartered in Calgary, Canada, Willow and its team of scientists are leaders in the field of biosynthetic production of high-value, plant-derived compounds. Willow has applied its integrated suite of technologies to develop manufacturing processes for numerous active pharmaceutical ingredients with various therapeutic benefits, including cancer treatment, pain management and CNS disorders. In the cannabinoid field, Willow owns proprietary, yeast-based lab strains that produce CBD, tetrahydrocannabinol (THC) and cannabigerol (CBG), as well as certain minor and novel cannabinoids. For more information, visit the company’s website at www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.